Citizens JMP lowered the firm’s price target on Structure Therapeutics (GPCR) to $87 from $89 and keeps an Outperform rating on the shares following the Q2 report. The firm says the company will release the Phase 2b data for aleniglipron by the end of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics Reports Q2 2025 Financial Results
- Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
- Structure Therapeutics files automatic mixed securities shelf
- Structure Therapeutics initiated with a Buy at Clear Street
- Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs